A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2010-10-29
- Last Posted Date
- 2016-04-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 173
- Registration Number
- NCT01230827
A Safety Study of CNTO 2476 in Patients With Age-Related Macular Degeneration
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-10-22
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 39
- Registration Number
- NCT01226628
A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-10-13
- Last Posted Date
- 2015-01-19
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 30
- Registration Number
- NCT01219010
Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-09-16
- Last Posted Date
- 2016-08-01
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 78
- Registration Number
- NCT01203631
- Locations
- 🇺🇸
Novo Nordisk Clinical Trial Call Center, Milwaukee, Wisconsin, United States
Efficacy of NNC0142-0002 in Subjects With Rheumatoid Arthritis (RA)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-08-13
- Last Posted Date
- 2016-10-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 63
- Registration Number
- NCT01181050
A Safety and Efficacy Study of JNS024 Extended Release (ER) in Japanese and Korean Patients With Chronic Malignant Tumor-Related Cancer Pain
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-07-19
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 343
- Registration Number
- NCT01165281
The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-06-04
- Last Posted Date
- 2015-01-15
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 756
- Registration Number
- NCT01137812
Pharmacokinetics and Safety Study of Tapentadol for Postsurgical Pain in Children and Adolescents
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 45
- Registration Number
- NCT01134536
Safety and Efficacy of EVT 101 in Treatment-Resistant Depression
- First Posted Date
- 2010-05-21
- Last Posted Date
- 2016-03-28
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 8
- Registration Number
- NCT01128452
- Locations
- 🇺🇸
Evotec Study Site 1, Baltimore, Maryland, United States
🇺🇸Evotec Study Site 12, Houston, Texas, United States
🇺🇸Evotec Study Site 2, Oak Brook, Illinois, United States
A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2010-05-03
- Last Posted Date
- 2013-02-13
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT01114698
© Copyright 2024. All Rights Reserved by MedPath